Complex Oncology Center Ruse EOOD

Ruse 14 trials 7 recruiting

14 Registered trials

7 Currently recruiting

Organisation

Complex Oncology Center Ruse EOOD

Location

Ruse, Bulgaria

Identifier

ORG-100046689

Address

Ulitsa Tsirkovna Nezavisimost 2, 7000, Bulgaria

Departments

Department - Medical Oncology Level II
Department – Medical Oncology Level II
Department of Medical Oncology
Department of Medical Oncology,
Hematology
Medical Oncology Department
Medical Oncology Level II

Clinical trials at this site (14)

Search interface

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting

2023-509179-18-00 Castration Resistant Prostate Cancer (CRPC) 1 2019-08-13
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 4 2023-05-30
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended

2023-507148-35-00 Chemotherapy-induced Thrombocytopenia in Adult Subjects 5 2019-10-03